Article
Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial.
Nature medicine - 1 Oct 2025
Drummond Katharine J, Spiteri Montana, Cain Sarah A, Jones Jordan, Shaya Sammy, Topp Monique, Lu Tianyao, Tobler Robert, Valkovic Adam L, Moore Zachery, Fatunla Oluwaseun E, Kriel Jurgen, Moffet Joel J D, McAlpine Heidi, Rosier Marius, Guan Hefei, Dimou James, Schadewaldt Verena, Roberts-Thomson Samuel, McArdle David, Lui Elaine, Voelker-Albert Moritz, di Sanzo Simone, Nijagal Brunda, Narayana Vinod K, Mitchell Camilla B, Vissers Joseph H A, Grimmond Sean, Rosenthal Mark A, Palmer Lucy M, Best Sarah A, Freytag Saskia, Whittle James R
Abstract excerpt
Mutant isocitrate dehydrogenase (mIDH) inhibition significantly improves progression-free survival in patients with mIDH WHO grade 2 glioma; however, a large proportion of patients will progress, and mechanisms of adaptation to mIDH inhibition remain poorly understood. Perioperative studies with evaluation of paired pre- and post-treatment samples enable detailed understanding of drug response, facilitating...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.